Sandoz Decision Increases Importance of Post-Grant Proceedings to Biosimilar Developers
- Timothy J. Shea, Jr. and Paul A. Calvo, Ph.D.
- IP Litigator
In this article published by IP Litigator, Timothy J. Shea, Jr. and Paul A. Calvo, Ph.D. discuss the recent decision in Sandoz, Inc. v. Amgen, Inc. On December 5, 2014, the U.S. Court of Appeals for the Federal Circuit rendered its decision in Sandoz v. Amgen, No. 2014-1693, a case with major implications for the emerging U.S. biosimilars industry. The decision addresses when and how a party seeking to launch a biosimilar product in the U.S. can initiate litigation to challenge the brand company’s potential blocking patents. This is the first instance in which the Federal Circuit has had the opportunity to address the scope and applicability of the Biologics Price Competition and Innovation Act (BPCIA), which established a formal pathway for biosimilar approval in the US.
To read the full article in IP Litigator, download the attached PDF.